Pharmaceutics and Advanced Drug Delivery Systems

September 1-2, 2022 | Italy

Pharmaceutics and Advanced
4th International Conference on Pharmaceutics and Advanced Drug Delivery Systems will welcome you to Rome, Italy September 1-2, 2022.

Spotlight

When it comes to enlisting the cancer-fighting potential of the body’s immune defenses, Amgen believes versatility is a virtue. Dave Reese discusses Amgen’s growing cancer immunotherapy research capabilities. Large numbers of immune cells (T cells in particular) are frequently found within or adjacent to melanoma tumors, indicating that the tumors attract the attention—if not the action—of the immune system. True to its reputation as one of the most ‘immunogenic‘ cancers, melanoma now has more U.S. Food and Drug Administration (FDA)-approved immunotherapy (immune system-targeting) drugs than any other cancer type. As a consequence, metastatic melanoma is no longer the universally fatal disease it was even just 3 or 4 years ago.


OTHER PAST CONFERENCES

19th Annual Pharma Data Congress

September 8-9, 2022 | UK

Showcasing success in FAIR data implementation, data analytics in drug discovery, AI/ML technologies, RWE management, data storage & infrastructure, multi-omic data integration and management

Temperature Controlled Logistics And Security

September 20-22, 2022 | USA

We are the world’s most innovative and educational event covering all you need to know about optimizing your end-to-end supply chain from a patient-centric, regulatory-compliant and cost effective perspective.

International Conference on Pain Medicine and Management

September 14-15, 2022 | USA

International Conference on Pain Medicine and Management September 19-20, 2022 Virtual Event

WORLD CONGRESS OF PHARMACY AND PHARMACEUTICAL SCIENCES

September 18-August 22, 2022 | Spain

At this critical time, when the challenges presented by the COVID-19 pandemic are still current and on the minds of healthcare professionals, we must take the opportunity to create more comprehensive plans to better manage health crises that may be on the horizon.

Spotlight

When it comes to enlisting the cancer-fighting potential of the body’s immune defenses, Amgen believes versatility is a virtue. Dave Reese discusses Amgen’s growing cancer immunotherapy research capabilities. Large numbers of immune cells (T cells in particular) are frequently found within or adjacent to melanoma tumors, indicating that the tumors attract the attention—if not the action—of the immune system. True to its reputation as one of the most ‘immunogenic‘ cancers, melanoma now has more U.S. Food and Drug Administration (FDA)-approved immunotherapy (immune system-targeting) drugs than any other cancer type. As a consequence, metastatic melanoma is no longer the universally fatal disease it was even just 3 or 4 years ago.

resources